Literature DB >> 3154709

Effect of intravenous ketanserin on the human action potential duration at fixed heart rate.

A J Drake-Holland1, M I Noble, S Pugh, C Mills.   

Abstract

In this study any changes in action potential duration or Q-T interval due to acute doses of ketanserin were monitored. The effect of a bolus dose (10 or 20 mg) followed by an infusion (10 or 20 mg over 20 minutes) of ketanserin on the Q-T interval and action potential duration was studied in six patients undergoing routine cardiac catheterization. Action potential duration was measured with a silver-silver chloride electrode catheter while heart rate was kept constant by atrial pacing and reflex effects avoided by beta-adrenergic blockade. There were some prolongations of the action potential duration but they were not in excess of 40 msec and did not reach statistical significance (control 263 +/- 46.0 msec; bolus 269 +/- 52.1 msec; infusion 262 +/- 53.6 msec; nor were there any significant changes in Q-T interval. Thus acute intravenous doses of ketanserin, in the absence of hypokalaemia or other Q-T interval-prolonging drugs, have no consistent effect on Q-T interval or action potential duration; prolongation of the action potential, when it occurs, is small.

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 3154709     DOI: 10.1007/bf00051240

Source DB:  PubMed          Journal:  Cardiovasc Drugs Ther        ISSN: 0920-3206            Impact factor:   3.727


  10 in total

1.  Comparison of cardiac monophasic action potentials recorded by intracellular and suction electrodes.

Authors:  B F HOFFMAN; P F CRANEFIELD; E LEPESCHKIN; B SURAWICZ; H C HERRLICH
Journal:  Am J Physiol       Date:  1959-06

Review 2.  Serotonin and the heart: effects of ketanserin on myocardial function, heart rate, and arrhythmias.

Authors:  S Saman; F Thandroyen; L H Opie
Journal:  J Cardiovasc Pharmacol       Date:  1985       Impact factor: 3.105

3.  In vitro validation of a new cardiac catheter technique for recording monophasic action potentials.

Authors:  M R Franz; D Burkhoff; H Spurgeon; M L Weisfeldt; E G Lakatta
Journal:  Eur Heart J       Date:  1986-01       Impact factor: 29.983

4.  International conference on the management of cardiac arrhythmias. London, England, September 2-4, 1987. Abstracts.

Authors: 
Journal:  Pacing Clin Electrophysiol       Date:  1987-07       Impact factor: 1.976

5.  Multiple serotonin receptors: differential binding of [3H]5-hydroxytryptamine, [3H]lysergic acid diethylamide and [3H]spiroperidol.

Authors:  S J Peroutka; S H Snyder
Journal:  Mol Pharmacol       Date:  1979-11       Impact factor: 4.436

6.  Is action potential duration of the intact dog heart related to contractility or stimulus rate?

Authors:  A J Drake; M I Noble; V Schouten; A Seed; H E Ter Keurs; B Wohlfart
Journal:  J Physiol       Date:  1982-10       Impact factor: 5.182

7.  Cardiac action potential duration and contractility in the intact dog heart.

Authors:  A J Drake-Holland; M I Noble; M Pieterse; V J Schouten; W A Seed; H E ter Keurs; B Wohlfart
Journal:  J Physiol       Date:  1983-12       Impact factor: 5.182

8.  Relation of human cardiac action potential duration to the interval between beats: implications for the validity of rate corrected QT interval (QTc).

Authors:  W A Seed; M I Noble; P Oldershaw; R B Wanless; A J Drake-Holland; D Redwood; S Pugh; C Mills
Journal:  Br Heart J       Date:  1987-01

9.  The action-potential duration and contractile response of the intact heart related to the preceding interval and the preceding beat in the dog and cat.

Authors:  G Elzinga; M J Lab; M I Noble; D E Papadoyannis; J Pidgeon; A Seed; B Wohlfart
Journal:  J Physiol       Date:  1981-05       Impact factor: 5.182

10.  On the change of cardiac action potential with age: a study in dogs.

Authors:  H Bosker; A J Drake-Holland; H E ter Keurs; M I Noble; J E Passingham; J R Pepper; M J Main; R B Wanless
Journal:  Cardiovasc Res       Date:  1985-11       Impact factor: 10.787

  10 in total
  2 in total

Review 1.  Ketanserin. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic potential in hypertension and peripheral vascular disease.

Authors:  R N Brogden; E M Sorkin
Journal:  Drugs       Date:  1990-12       Impact factor: 9.546

2.  Acute electrophysiologic effects of an HT2-serotonin antagonist, ketanserin, in humans.

Authors:  G C Kaye; D Mehta; S Wafa; A J Camm
Journal:  Cardiovasc Drugs Ther       Date:  1990-08       Impact factor: 3.727

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.